Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


All chapters
Previous chapter Next chapter

Chapter 5

Kinase Mutations and Resistance in Cancer

The story of kinase inhibitors as drugs is largely also the story of the interplay between kinase mutations and drug discovery for cancer.1 In 2001, the small molecule kinase inhibitor, imatinib mesylate (Gleevec, 5.1) was first approved for use in various leukemias in the United States.2 This drug ...

Publication details


Print publication date
06 Dec 2011
Copyright year
2012
Print ISBN
978-1-84973-174-4
PDF eISBN
978-1-84973-355-7
From the book series:
Drug Discovery